NextCure (NXTC) Competitors $5.30 -0.15 (-2.67%) Closing price 09/12/2025 03:50 PM EasternExtended Trading$5.38 +0.08 (+1.51%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC vs. INMB, BRNS, ATNM, FGEN, TPST, VRCA, LTRN, PEPG, NBRV, and RNXTShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include INmune Bio (INMB), Barinthus Biotherapeutics (BRNS), Actinium Pharmaceuticals (ATNM), FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Its Competitors INmune Bio Barinthus Biotherapeutics Actinium Pharmaceuticals FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma PepGen Nabriva Therapeutics RenovoRx INmune Bio (NASDAQ:INMB) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Do institutionals and insiders have more ownership in INMB or NXTC? 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 35.7% of INmune Bio shares are held by insiders. Comparatively, 17.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is INMB or NXTC more profitable? NextCure's return on equity of -106.62% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -120.62% -92.94% NextCure N/A -106.62%-85.20% Do analysts recommend INMB or NXTC? INmune Bio presently has a consensus price target of $18.40, suggesting a potential upside of 815.42%. NextCure has a consensus price target of $25.50, suggesting a potential upside of 381.59%. Given INmune Bio's higher probable upside, equities research analysts clearly believe INmune Bio is more favorable than NextCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57NextCure 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has higher earnings and valuation, INMB or NXTC? INmune Bio has higher revenue and earnings than NextCure. INmune Bio is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$50K1,068.72-$42.08M-$2.48-0.81NextCureN/AN/A-$55.65M-$25.82-0.21 Which has more risk and volatility, INMB or NXTC? INmune Bio has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, NextCure has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Does the media prefer INMB or NXTC? In the previous week, INmune Bio and INmune Bio both had 2 articles in the media. NextCure's average media sentiment score of 1.45 beat INmune Bio's score of 0.64 indicating that NextCure is being referred to more favorably in the news media. Company Overall Sentiment INmune Bio Positive NextCure Positive SummaryINmune Bio and NextCure tied by winning 7 of the 14 factors compared between the two stocks. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.56M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.2121.1774.5225.93Price / SalesN/A427.59516.43181.21Price / CashN/A46.6837.5660.44Price / Book0.199.6112.166.29Net Income-$55.65M-$53.29M$3.28B$270.77M7 Day Performance7.73%0.12%0.78%3.84%1 Month Performance2.02%5.60%4.87%4.85%1 Year Performance-68.48%10.47%60.72%26.00% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.7441 of 5 stars$5.30-2.7%$25.50+381.6%-68.0%$14.56MN/A-0.2190Positive NewsShort Interest ↓Gap DownINMBINmune Bio2.9878 of 5 stars$1.81-7.2%$18.40+916.6%-68.5%$51.84M$10K-0.7310Short Interest ↓BRNSBarinthus Biotherapeutics2.9997 of 5 stars$1.22-2.0%$3.00+146.9%-14.1%$50.49M$14.97M-0.70107Positive NewsGap UpATNMActinium Pharmaceuticals3.071 of 5 stars$1.60+1.3%$4.50+181.3%-16.2%$49.91MN/A-1.1530Short Interest ↑FGENFibroGen4.4848 of 5 stars$11.16-7.8%$43.00+285.3%+13.7%$48.93M$29.62M-29.37570News CoverageAnalyst UpgradeGap DownTPSTTempest Therapeutics2.4642 of 5 stars$10.85-1.3%$30.00+176.5%-40.7%$48.80MN/A-0.7420Positive NewsVRCAVerrica Pharmaceuticals4.0843 of 5 stars$5.06-1.0%$80.00+1,481.0%-75.5%$48.22M$7.57M-0.6140LTRNLantern Pharma2.5962 of 5 stars$4.06-5.8%$25.00+515.8%+1.1%$46.54MN/A-2.2820PEPGPepGen2.8379 of 5 stars$1.49+6.4%$7.67+414.5%-83.6%$45.92MN/A-0.5030Analyst ForecastGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3558 of 5 stars$1.14-8.1%$7.50+557.9%+19.6%$45.44M$40K-3.006News CoverageShort Interest ↑Gap Up Related Companies and Tools Related Companies INMB Competitors BRNS Competitors ATNM Competitors FGEN Competitors TPST Competitors VRCA Competitors LTRN Competitors PEPG Competitors NBRV Competitors RNXT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXTC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NXTC Stock Alerts